These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35659487)

  • 21. Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay.
    Arbo A; Martinez-Cuellar C; Vazquez C; Bellier L; Adorno C; Dibarboure H; Lopez JG; Petitjean A; Bianculli P
    Hum Vaccin Immunother; 2022 Nov; 18(5):2069974. PubMed ID: 35543602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales.
    Mattock R; Gibbons I; Moss J; Mealing S; Largeron N; Carroll S; Alvarez FP
    J Med Econ; 2021; 24(1):1261-1271. PubMed ID: 34726129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program.
    Zeevat F; Crépey P; Dolk FCK; Postma AJ; Breeveld-Dwarkasing VNA; Postma MJ
    Value Health; 2021 Jan; 24(1):3-10. PubMed ID: 33431150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
    You JH; Ming WK; Chan PK
    Hum Vaccin Immunother; 2015; 11(3):564-71. PubMed ID: 25714506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis.
    Zhu D; Lv M; Bai Y; Wu J; He P
    Vaccine; 2022 Feb; 40(7):994-1000. PubMed ID: 35065820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
    de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
    Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.
    Thommes EW; Kruse M; Kohli M; Sharma R; Noorduyn SG
    Hum Vaccin Immunother; 2017 Apr; 13(4):867-876. PubMed ID: 27858509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials.
    Moa AM; Chughtai AA; Muscatello DJ; Turner RM; MacIntyre CR
    Vaccine; 2016 Jul; 34(35):4092-4102. PubMed ID: 27381642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis.
    Minozzi S; Lytras T; Gianola S; Gonzalez-Lorenzo M; Castellini G; Galli C; Cereda D; Bonovas S; Pariani E; Moja L
    EClinicalMedicine; 2022 Apr; 46():101331. PubMed ID: 35360146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United States.
    Net P; Colrat F; Nascimento Costa M; Bianic F; Thommes E; Alvarez FP
    Vaccine; 2021 Mar; 39 Suppl 1():A56-A69. PubMed ID: 33509695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population.
    Tavares D; Mouriño H; Rodríguez CA; Saborido CM
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.
    McElhaney JE; Beran J; Devaster JM; Esen M; Launay O; Leroux-Roels G; Ruiz-Palacios GM; van Essen GA; Caplanusi A; Claeys C; Durand C; Duval X; El Idrissi M; Falsey AR; Feldman G; Frey SE; Galtier F; Hwang SJ; Innis BL; Kovac M; Kremsner P; McNeil S; Nowakowski A; Richardus JH; Trofa A; Oostvogels L;
    Lancet Infect Dis; 2013 Jun; 13(6):485-96. PubMed ID: 23518156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Bellier L; Petitjean A; Sarazu T; Tresierra J; Lopez JG
    Vaccine; 2021 Jul; 39(30):4144-4152. PubMed ID: 34130885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of Influenza Vaccination Strategies in Adults: Older Adults Aged ≥65 Years, Adults Aged 50-64 Years, and At-Risk Adults Aged 19-64 Years.
    Choi MJ; Shin G; Kang D; Lim JO; Kim YK; Choi WS; Yun JW; Noh JY; Song JY; Kim WJ; Choi SE; Cheong HJ
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivated influenza virus vaccines: the future of TIV and QIV.
    Schotsaert M; García-Sastre A
    Curr Opin Virol; 2017 Apr; 23():102-106. PubMed ID: 28505524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany.
    Kohli MA; Maschio M; Cartier S; Mould-Quevedo J; Fricke FU
    Vaccines (Basel); 2022 Aug; 10(9):. PubMed ID: 36146464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quadrivalent versus trivalent influenza vaccine: clinical outcomes in two influenza seasons, historical cohort study.
    Shasha D; Valinsky L; Hershkowitz Sikron F; Glatman-Freedman A; Mandelboim M; Toledano A; Paran Y; Ben-Ami R; Goldman D
    Clin Microbiol Infect; 2020 Jan; 26(1):101-106. PubMed ID: 31108229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
    Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.